Articles tagged with Breast Cancer
A collaboration between George Mason University and Rutgers Cancer Institute aims to validate a new test for measuring HER2 biomarkers, which can predict patient response to treatment. The test uses advanced technology to analyze tissue samples and identify specific therapies for individual patients.
New study reveals that breast cancer mortality rates have stopped decreasing among women aged 20-39, with distant-stage cancers on the rise. Researchers attribute this change to increased incidence of late-stage breast cancers, highlighting the importance of mammography screening for early detection.
A new drug, ProAgio, has been shown to be effective in treating pancreatic cancer and prolonging survival in mice. It works by inducing apoptosis in cancer-associated fibroblasts, reducing the dense stroma that protects tumors from immune systems and conventional drugs.
A mammography screening strategy based on a baseline breast density measure at age 40 is the most effective and cost-effective way to reduce breast cancer mortality. The study suggests that this approach can lead to a significant reduction in breast cancer mortality, but also increases the number of mammograms performed and false posit...
UC researchers discovered that stopping autophagy in cancer cells can help treat HER2-positive breast cancer. By blocking this process, cancer cells were unable to develop and grow, and the HER2 protein was altered in a way that prevented its role in cancer development.
Researchers aim to establish a quantitative cut point assay level for HER2+ breast cancer using pCR. They will also validate the test on a retrospective cohort of patients receiving standard-of-care treatment at the Rutgers Cancer Center.
A randomized clinical trial found that endocrine therapies can reduce estradiol levels in men with hormone receptor-positive breast cancer after three months of treatment. The study suggests a potential new approach for male breast cancer patients.
The CIC biomaGUNE BioNanoPlasmonics research team has grown three-dimensional tumours in scaffolds containing plasmonic nanoparticles to study cancer growth and dynamics. They aim to gain insight into tumour evolution over time by monitoring metabolites, temperature, and pH.
Researchers found that long-term occupational exposure to sunlight is associated with a lower risk of breast cancer in women after the age of 50. Vitamin D levels may protect against the disease, but the study's limitations highlight the need for further investigation.
A national survey found that four-fifths of US physicians believe significant disabilities are associated with worse quality of life. The study highlights the need for medical education to include training on disability and awareness of unconscious bias.
A recent study discovered that SORLA protein plays a crucial role in the growth of breast cancer cells in the brain and their resistance to HER2 therapy. Removing SORLA from cancer cells sensitizes them to anti-HER2 treatment, offering new possibilities for targeting drug-resistant cancers.
Researchers discovered that the RPS-12 protein triggers triple-negative breast cancer and possibly other malignancies by activating an important signaling pathway. The protein's overproduction also leads to developmental abnormalities in fruit fly eyes.
A study of 44,541 women found that taking metformin to treat type 2 diabetes may protect against developing ER-positive breast cancer. However, the risk of triple negative breast cancer was increased by 74% among those treated with metformin. The link between type 2 diabetes and breast cancer varied by breast cancer subtype.
A nationwide panel developed guidelines recommending discontinuing routine mammograms for survivors with a life expectancy under five years. Guidelines also suggest stopping screening for those with a 5-10-year life expectancy, and continuing annual or biennial mammography when life expectancy exceeds 10 years.
A new machine learning algorithm named Mirai estimates breast cancer risk in women more accurately than current models, identifying 41.5% of patients at risk within 5 years. The model was effective across various races and ethnicities, supporting its potential to inform screening guidelines for diverse populations.
Breast cancer cells can evade immune attacks by increasing the level of protein MAL2 on their surface, leading to enhanced tumor growth. Targeting this action could improve immunotherapy for patients. Researchers identified MAL2 as a key protein and found that inhibiting it can almost completely stop tumor growth.
A TGen-led study has developed a test to detect infinitesimally small breast cancer biomarkers in blood samples, improving detection accuracy. The test uses a highly specific protein signature to identify the earliest stages of breast cancer with no false positives.
Researchers at UToledo have received funding to advance a new chemotherapy treatment for triple negative breast cancer, which shows promise in overcoming multidrug resistance. The treatment targets a unique cell death pathway, potentially offering new hope for patients with poor prognosis.
Researchers found that time-restricted feeding, a form of intermittent fasting aligned with circadian rhythms, improved metabolic health and reduced tumor growth in mice with obesity-driven postmenopausal breast cancer. Elevated insulin levels drove accelerated tumor growth, which was mitigated by reducing insulin levels.
A new multi-institution study provides more accurate estimates of breast cancer risk for US women with inherited mutations in breast cancer predisposition genes. The findings may allow healthcare providers to better assess the risk of breast cancer and provide more appropriate risk management strategies.
A study found that Anastrozole-induced bone loss partially reverses, especially at the lumbar spine, when treatment is stopped. The results suggest improved bone health, encouraging physicians to weigh risks and benefits in high-risk women eligible for the drug.
Researchers at NUI Galway have contributed to a significant international study identifying nine specific genes linked to breast cancer risk. The study, published in the New England Journal of Medicine, used DNA samples from 2,000 Irish patients and controls to uncover key genetic associations.
A recent study published in JAMA Oncology found significant racial disparities in breast cancer prognosis testing among Black women, who have higher recurrence and mortality rates than non-Hispanic white women. The study suggests that genomic tumor tests may require re-calibration to reflect racial differences.
The Minnesota Partnership has awarded five teams with nearly $5 million in research grants to develop a long-lasting COVID-19 vaccine, new treatments for breast and other cancers, and gene-editing techniques to prevent birth defects. The projects will focus on improving treatment of diseases such as cancer and genetic disorders.
A large international consortium has identified nine genes that increase breast cancer risk, which can now be used to personalize follow-up and screening programs. The study analyzed 113,000 samples and confirms the importance of these genes in predicting breast cancer risk.
A new drug targeting enzymes involved in myristoylation has shown promise in treating both breast and blood cancers. Researchers found that patients with specific enzyme NMT2 were more likely to die, and the drug slowed tumour growth by 90% in mice with human breast cancer.
Scientists have discovered a link between nicotine and the spread of breast cancer cells into the lungs, which can lower survival rates by 33%. Nicotine exposure creates an environment ripe for metastatic growth, attracting immune cells that promote tumor growth.
Researchers have identified a molecular crowbar that enables cancer cells to invade surrounding tissues. Hepsin, normally a glue-like protein, becomes a destructive enzyme when activated by Ras, leading to the breakdown of the basement membrane and cancer cell invasion.
Researchers have found that androgen receptor activation by natural androgens or a new drug has potent anti-tumour activity in all estrogen receptor positive breast cancers, even those resistant to current treatments. This study provides new evidence for an alternative treatment strategy.
Researchers at RCSI University of Medicine and Health Sciences have discovered a molecule, BAS-2, that selectively kills cells of triple negative breast cancer while sparing normal cells. The molecule inhibits an enzyme called HDAC6, playing a key role in altering energy in these cancer cells.
Researchers developed CopyKAT, a new computational technique that accurately differentiates between cancer and normal cells in solid tumor samples. The tool uses gene expression data to identify aneuploidy and distinct subpopulations within cancer cells.
A team of engineers at Rensselaer Polytechnic Institute developed an in vitro lymphatic vessel model to study tumor emboli growth. Researchers found that the model showed different growth behaviors based on cell type, linked to force generation capability, and has implications for therapeutic design.
A new study published in Cell reveals that RNA splicing therapeutics can activate antiviral immune pathways in triple negative breast cancers, triggering tumor cell death and signaling the body's immune response. The discovery highlights a novel mechanism for turning on the immune system in aggressive cancers.
A new risk assessment tool, CARG-BC Score, helps oncologists make personalized treatment recommendations for elderly patients with early-stage breast cancer. The score combines eight disease and patient-reported predictors to predict the likelihood of severe chemotherapy side effects.
A team of UT Southwestern researchers has identified the gene ZMYND8 as being increased in breast cancer conditions and correlating with poor survival rates. The gene regulates DNA stability and inhibits antitumor immunity, but removing or inhibiting it allows lymphocytes to invade tumors and prevent growth.
A new study suggests that Dense Breast Notifications (DBNs) have achieved partial success in informing women about their breast density, with higher rates of notification and discussions with providers in states with mandated DBN laws. However, the study also found disparities in knowledge and awareness among women of different race/et...
A new study found that up to 20% of glioblastomas are fueled by overactive mitochondria, making them potentially treatable with current clinical trial drugs. Researchers discovered four types of brain cancer, including the mitochondrial subtype, which has a slightly better prognosis.
Scientists at The Wistar Institute have developed an ACSS2 inhibitor that impairs cancer growth in preclinical models by depriving malignant cells of a critical nutrient source. This approach targets acetate metabolism, which is essential for tumor growth under conditions of low nutrient and oxygen availability.
A study from Johns Hopkins Medicine reveals that exposure to B. fragilis toxin can increase the risk of breast cancer by leaving a lasting impression on cells. Researchers found that breast tissue cells exposed to the toxin retained a long-term memory, leading to tumor growth and metastasis in mice.
A uOttawa study finds that mindfulness can significantly impact the brain of women suffering from neuropathic pain related to breast cancer treatment. The research shows major reductions in brain activity and a significant improvement in brain health as well as pain perception.
A new study suggests that adding a small molecule to CAR-T cell therapy can boost the effectiveness of immunotherapy against breast cancer and other solid tumors. Researchers found that the addition of cGAMP activated an immune response, leading to enhanced T cell proliferation and tumor growth reduction.
Researchers found that combining CAR T cells with a proinflammatory environment created by STING pathway activation can improve their ability to attack tumor cells. This approach, combined with therapeutic antibodies, led to the complete eradication of breast tumors in mice.
Researchers found that surgery in addition to treatments like chemotherapy and radiation therapy increased survival for stage four breast cancer patients. Patients with hormone receptor-positive tumors saw a prolonged length of survival when their treatment plan included surgery.
Researchers developed two new mammogram-based measures of risk, combining them to predict breast cancer risk more effectively than known genetic and breast density factors. The new measures could improve screening, reduce mortality, and make it less stressful for women.
Researchers found that surgery in addition to treatments like chemotherapy and radiation therapy increased the length of survival for stage four breast cancer patients. The study, published in Annals of Surgical Oncology, suggests that knowing a cancer's biological subtype can help determine effective treatment plans.
Researchers at CSHL have discovered a gene-regulating RNA that contributes to breast cancer metastasis. By targeting this RNA, they found a molecule that can reduce tumor growth and metastases in animal experiments.
A recent study found that macrophages play a crucial role in suppressing the effectiveness of PARP inhibitor therapy in breast cancer patients. The researchers identified CSF-1R-positive macrophages as the key suppressive cells, which can be targeted to enhance anti-tumor responses.
A new study by MIT scholars suggests that mammogram screening may be more effective for targeted testing, rather than age-based recommendations. Women who start getting mammograms at age 40 are found to be healthier and less likely to have cancer, making targeting higher-risk groups a potential solution.
A type of immune cell known as regulatory T cells acts as a major driver of breast cancer growth by preventing the accumulation of a specific protein that induces anti-tumor responses. Targeting these cells could lead to improved treatment outcomes for patients.
A new RNA drug-discovery tool called Chem-CLIP-Fragment Mapping has been developed to address the challenge of 'undruggable' proteins. The tool uses functionalized fragments that can bind to RNAs and modify their structure, enabling the design of medicines against previously untreatable diseases.
A clinical trial combining microbubbles with radiation therapy has shown promising results in treating liver cancer. The treatment increased tumor response rates by 93% compared to standard radiation alone, and improved patient outcomes, including longer overall survival and reduced need for retreatments.
Researchers developed a polygenic risk score to assess breast cancer risk in carriers of high-risk mutations. The score provides a more accurate estimate, especially for close relatives, and has the potential to save lives by targeting cancer screening.
A study published in Journal of the American College of Surgeons found that financial toxicity among breast cancer patients is independently associated with worse psychological well-being. Even small improvements in financial pressure can lead to better mental well-being and higher patient satisfaction with breast reconstruction.
ReceptorNet, a deep-learning algorithm developed by Salesforce Research, can determine hormone-receptor status from inexpensive tissue images, improving treatment decision-making for breast cancer patients. This technology has the potential to make high-quality therapies more accessible globally.
A new study suggests that targeting the RANK signaling pathway can enhance antitumor immune responses, making breast cancer more responsive to immunotherapy. The findings come from a clinical trial and preclinical research, demonstrating the potential of this approach to convert 'cold' tumors into 'warm' ones.
Researchers found that adding an immune checkpoint inhibitor to standard chemotherapy for patients with early-stage breast cancer does not decrease their ability to perform daily activities. The study, based on data from the IMpassion031 trial, showed increased response rates and no significant impact on quality of life.
Women who receive mastectomy and reconstructive surgery are at increased risk of developing persistent use of opioids and sedative-hypnotic drugs. The study found that 13.1% of patients become new persistent opioid users after surgery, while 6.6% develop persistent sedative-hypnotic use.
A clinical trial found that postmenopausal women with low-risk breast cancer can forego chemotherapy without compromising their treatment outcomes. In contrast, premenopausal women with the same disease characteristics benefit from chemotherapy, suggesting a potential age-related difference in treatment effectiveness.
The new guidelines provide uniform standards for treating brain tumour complications such as epileptic attacks, brain edema, haemorrhage, or thrombosis worldwide. The initiative aims to increase patient safety and improve treatment outcomes.
Extended follow-up data from the monarchE trial shows that abemaciclib continues to improve IDFS among high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer patients. The addition of abemaciclib to standard adjuvant endocrine therapy reduces the risk of invasive disease by 25 percent.